Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12996125 | 0.80 | ALOX12 (0.43) | ALOX12DYRK1ASSTR4IDO1TDP1 | |
| SCHEMBL9607546 | 0.80 | ALOX12 (0.56) | ALOX12DYRK1ASSTR4IDO1TDP1 | |
| SCHEMBL12203138 | 0.79 | DYRK1A (0.51) | ALOX12DYRK1ASSTR4IDO1TDP1 | |
| SCHEMBL17033304 | 0.76 | ALOX12 (0.50) | ALOX12DYRK1ATDP1CYP1A2KDM4E | |
| SCHEMBL17039300 | 0.71 | DYRK1A (0.51) | ALOX12DYRK1ATDP1CYP1A2KDM4E | |
| SCHEMBL22340027 | 0.70 | MAPK8 (0.58) | DYRK1AIDO1MAPK1GAAMAPT | |
| SCHEMBL16252862 | 0.70 | SSTR4 (0.50) | ALOX12DYRK1ASSTR4IDO1TDP1 | |
| SCHEMBL20878604 | 0.66 | DYRK1A (0.45) | ALOX12DYRK1AIDO1TDP1CYP1A2 | |
| SCHEMBL17554526 | 0.64 | ALOX12 (0.59) | ALOX12DYRK1ATDP1CYP1A2MAPK1 | |
| SCHEMBL23429365 | 0.63 | SALL4 (0.39) | KDM4EMAPK1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190185498-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10253053-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190023729-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | ALOX12 261/4885DYRK1A 4649/4885SSTR4 4654/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | ALOX12 76/4885DYRK1A 4471/4885SSTR4 1711/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | ALOX12 173/4885DYRK1A 4589/4885SSTR4 2848/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | ALOX12 370/4885DYRK1A 4826/4885SSTR4 3296/4885 |
| US-20180072762-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | ALOX12 76/4885DYRK1A 4471/4885SSTR4 1711/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | ALOX12 374/4885DYRK1A 4766/4885SSTR4 4258/4885 |
| US-20180030075-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | ALOX12 137/4885DYRK1A 3853/4885SSTR4 3019/4885 |
| US-10464956-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | ALOX12 164/4885DYRK1A 3870/4885SSTR4 2748/4885 |
| US-10253053-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | ALOX12 164/4885DYRK1A 3870/4885SSTR4 2748/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | ALOX12 370/4885DYRK1A 4826/4885SSTR4 3296/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | ALOX12 183/4885DYRK1A 4330/4885SSTR4 3642/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ALOX12 235/4885DYRK1A 4035/4885SSTR4 1891/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | ALOX12 125/4885DYRK1A 4542/4885SSTR4 3742/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | ALOX12 160/4885DYRK1A 4787/4885SSTR4 2229/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | ALOX12 164/4885DYRK1A 3870/4885SSTR4 2748/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | ALOX12 160/4885DYRK1A 4787/4885SSTR4 2229/4885 |
| US-20190023729-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | ALOX12 164/4885DYRK1A 3870/4885SSTR4 2748/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | ALOX12 183/4885DYRK1A 4330/4885SSTR4 3642/4885 |
| US-20190185498-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | ALOX12 164/4885DYRK1A 3870/4885SSTR4 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.